GlassScriptPhysician profile
Rasheshkumar B Dholakia
NPI 1487817722
$2,556.43
in general payments reported to CMS, 2019-2025
21 companies · $868 in 2025
The $868 reported for 2025 was more than what 84% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.66 · 2021: $11.48 · 2022: $191 · 2023: $732 · 2024: $727 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $508.72 | 2022-2025 | Azstarys |
| Abbvie INC. | $353.49 | 2023-2025 | Vraylar |
| Axsome Therapeutics, INC. | $236.22 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $212.59 | 2023-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $195.22 | 2021-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $189.83 | 2019-2024 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $144.81 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $114.30 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $88.61 | 2022-2024 | Jornay Pm |
| Tris Pharma INC | $75.50 | 2023-2025 | Onyda Xr, Dyanavel Xr |
| Neurocrine Biosciences, INC. | $66.09 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.35 | 2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $53.94 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $49.54 | 2024-2025 | Xelstrym, Secuado |
| Bausch Health US, LLC | $45.54 | 2025 | Aplenzin, Wellbutrin |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $43.93 | 2025 | Rexulti |
| Vertical Pharmaceuticals, LLC | $37.36 | 2025 | Relexxii |
| Idorsia Pharmaceuticals US INC | $27.39 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $18.36 | 2022 | |
| Lilly USA, LLC | $17.81 | 2025 | Zepbound |
| Shire North American Group INC | $14.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rasheshkumar Dholakia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.